Advertisement

Topics

FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia

15:09 EDT 13 Sep 2018 | Drugs.com

September 13, 2018 -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have...

Original Article: FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement